Antibody-Drug Conjugates: An Emerging Class of Cancer Treatment
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 288
Special Issue Editor
Special Issue Information
Dear Colleagues,
Antibody–drug conjugates (ADCs) are drugs with enormous potential which are now established as a major class of therapeutics for the clinical treatment of cancer. To date, twelve ADCs have been approved by the FDA. ADCs are constructed with four main elements: a monoclonal antibody designed to target a particular cancer-associated antigen, a potent cytotoxic payload or warhead, a “linker” that cleaves off that payload inside cancer cells, and the conjugation technology that attaches the linker and payload to the antibody. ADCs provide a unique opportunity to deliver drugs to tumor cells, thus improving the efficacy of chemotherapy and reducing systemic exposure and toxicity. However, while this all sounds relatively straightforward, the construction has been anything but simple for ADC developers. Emerging linker technologies also raise the exciting possibility of attaching different payloads with different mechanisms of action to the same antibody to improve efficacy and reduction in the development of resistance. The quest for novel payload molecules is driven by several factors, including the need to enhance cytotoxic potency, avoid the development of resistance, and improve physicochemical properties.
In this Special Issue, we aim to publish high-quality manuscripts highlighting novel approaches for payload design and synthesis in the field of ADCs. We welcome manuscript submissions in the form of original research, communication, and perspectives.
Prof. Marie Claude Viaud-Massuard
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ADCs
- Payloads
- Duals
- Bioconjugation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
